- Erenumab 140 mg achieved 69.1% Medicine Overuse Headache remission at 6 months
- Erenumab 70 mg additionally diminished Medicine Overuse Headache however with out statistical significance
- Each doses considerably diminished acute headache treatment days in comparison with placebo
Continual migraine (CM) is a debilitating situation that impacts thousands and thousands of people worldwide. A big subset of sufferers with CM additionally suffers from Medicine Overuse Headache (MOH), a secondary headache dysfunction brought on by the extreme use of acute headache drugs. Erenumab, a calcitonin gene-related peptide (CGRP) receptor antagonist, has been studied for its potential to induce MOH remission in sufferers with persistent migraine (1✔ ✔Trusted Supply
Efficacy and Security of Erenumab for Nonopioid Medicine Overuse Headache in Continual Migraine
Go to supply
).
Findings of Efficacy and Security of Erenumab in Continual Migraine with Nonopioid Medicine Overuse Headache
The trial included 584 members within the nonopioid-treated cohort. The imply age of members was 44 years, with 82.5% of members being feminine (482 people). Baseline demographics and illness traits have been balanced throughout the research teams.
Contributors have been randomly assigned to obtain month-to-month injections of both Erenumab 140 mg or Erenumab 70 mg or Placebo.
The first endpoint of the research was the remission of MOH at month 6. Secondary endpoints included the discount in the usage of acute headache treatment days (AHMD) and the analysis of opposed occasions.
Efficacy in MOH Remission
The outcomes confirmed that erenumab was efficient in inducing MOH remission in sufferers with persistent migraine and nonopioid MOH:
- Erenumab, 140 mg group: 69.1% achieved MOH remission at month 6, with a statistically vital odds ratio (OR) of two.01 (95% CI, 1.33-3.05; P
- Erenumab, 70 mg group: 60.3% achieved MOH remission, with an OR of 1.37 (95% CI, 0.92-2.05; P = .13) in comparison with placebo.
- Placebo group: 52.6% achieved MOH remission.
Though each doses of erenumab demonstrated efficacy, solely the 140 mg dose met the statistical significance threshold for MOH remission in comparison with placebo.
Discount in Acute Headache Medicine Days (AHMD)
Contributors within the erenumab teams confirmed a major discount in AHMD in comparison with placebo:
- Erenumab, 140 mg: The least squares imply discount in AHMD was –9.4 days (distinction from placebo, –2.7; 95% CI, –3.9 to –1.6; P
- Erenumab, 70 mg: The discount in AHMD was –7.8 days (distinction from placebo, –1.2; 95% CI, –2.4 to –0.1; P = .03).
- Placebo group: The discount in AHMD was –6.6 days.
Sustained MOH Remission
MOH remission was sustained all through the 6-month double-blind remedy interval (DBTP):
- Erenumab, 140 mg group: 61.3% sustained remission
- Erenumab, 70 mg group: 49.5% sustained remission
- Placebo group: 37.6% sustained remission
Security Profile
The security of erenumab was in step with earlier research. The incidence of treatment-emergent opposed occasions within the mixed erenumab group was 66.8%. The commonest opposed occasions have been:
- Constipation: 15.2%
- COVID-19 infections: 13.9%
No new security considerations have been recognized through the trial.
The findings from this randomized medical trial display that month-to-month injections of 140 mg erenumab have been efficient in inducing MOH remission in sufferers with persistent migraine and nonopioid treatment overuse headache inside 6 months. The 70 mg dose confirmed some profit however didn’t meet the edge for statistical significance. Moreover, each doses of erenumab considerably diminished the usage of acute headache drugs, additional supporting its potential function in managing this difficult affected person inhabitants.
Commercial
These outcomes present sturdy proof for the usage of erenumab as a preventive remedy in sufferers with persistent migraine and drugs overuse complications, providing hope for higher administration of this burdensome situation.
Reference:
- Efficacy and Security of Erenumab for Nonopioid Medicine Overuse Headache in Continual Migraine – (https://jamanetwork.com/journals/jamaneurology/fullarticle/2823594?guestAccessKey=eaf63723-49d8-4ab9-b76b-b3c2d525b92d)
Supply-Medindia